https://www.selleckchem.com/pr....oducts/elexacaftor.h
3921 (2029) IU/kg/year/patient, p 0.028); a significant decrease in their ABR was also observed between T1 and T2 (6.3 (6. vs. 4.4 (5.4), p 0.047). These patients had a more severe bleeding profile centred on haemarthrosis. The results are related to those of the pivotal clinical trials for the reduction in FVIII consumption following the switch to rFVIII-Fc, with a significant improvement in the haemorrhagic phenotype for pwSHA. The results are related to those of the pivotal clinical trials for the reduction in FVIII consumption
Like
Comment
Share
